Read the article about Multi-OMICS for Risk Assessment and Progression of Diabetes within the IMI2 project RHAPSODY by Kirsten Leufgen (SCIPROM) and Oliver Uecke (Lipotype GmbH) in the German Magazine Transkript/Laborwelt (04/2017)
Multiomics approaches harness synergies and eliminate shortcomings to effectively deliver what one omics science alone cannot achieve. Lipotype’s new white paper “Unlocking the Power of Multiomics” highlights why combining genomics with lipidomics makes for a great omics pair.
Genomics for genes, lipidomics for lipids Being major players in cardiovascular disease research, genomics and lipidomics are perfectly suited for a joint multiomics approach. It matches the capacity to identify genetic predestinations with one or multiple snapshots of the lipid metabolic status.
Linking genotype with phenotype will be critical when it comes to clinical diagnostics and to the goal of identifying the onsets of a disease.
From genotype to phenotype: interconnected disease risk factors In this study, a large number of SNPs (single-nucleotide polymorphisms) from genomes was drawn. They were then correlated with corresponding lipid species levels from human blood plasma. The blood plasma has been analyzed with Lipotype Shotgun Lipidomics technology. The most important findings are the following.
First, the heritability of lipid species levels was quantified from the SNP correlations. Second, genetic predispositions influencing lipid species levels provide useful information for cardiovascular disease risk predictions. And third, lipidomics yields greater statistical power to identify SNPs with direct roles in lipid metabolism. Lipidomics outperforms traditional lipid panel measures used in clinical routine.
Lipotype contributed to an article about lipidomics in biotech and pharma on Technology Networks.
The article in short
Interest in lipidomics has been reignited for both, academia and industry. To cope with that, the article sums up various aspects, developments and differences in lipidomics technology. Such as Lipotype Shotgun Lipidomics technology.
Dr. Christian Klose, Head of Research and Development at Lipotype, had been interviewed to explain how to address the needs and questions of academia and industry. In the end, two researchers from academia and he give brief insights into the future of lipidomics. Both, research- and technology-wise.
Technology Networks is an online scientific publication platform. Their articles and reviews provide insights into the latest research, industry news, and technologies. Covering a wide bandwidth of scientific communities, they provide detailed coverage of analytical chemistry, life sciences, drug discovery, and neuroscience. As they enable readers to easily find reliable, digestible, and high-quality content, Technology Networks draws the attention of researchers on the science that matters to them.
July has been a great month. Three new publications with Lipotype Shotgun Lipidomics technology have been put out, and the Lipidomics Resource Center received its first major update. Read more about this!
One month – three publications
This month, three new publications with Lipotype Shotgun Lipidomics technology were published!
Paper 1: Parkinson’s disease In Parkinson’s, excessive contacts between mitochondria and endoplasmic reticulum lead to abnormal lipid trafficking. This stops the release of “sleep” peptides affecting sleep patterns of patients long before they experience motor dysfunctions…
Paper 2: vacciness Adjuvants like the well-established AS03 are agents in vaccines that do not provide immunity but stimulate the immune system. However, the molecular mechanism behind AS03’s adjuvant effect had yet to be fully illuminated. These new results could be applied to design novel vaccine adjuvants…
Paper 3: cancer therapeutics Oncogenic RAS proteins must localize to the plasma membrane to act. The recently described oxanthroquinone G01 disrupts that, affects levels of some lipids and synergizes with other compounds that affect oncogenic RAS proteins. G01 could become a new anti-RAS therapeutic…
We strive for scientific excellence, and therefore must hold on to the fact that all science is just as good as the research which precedes it. Therefore, we created the Lipidomics Resource Center which provides access to lipidomics publications and whitepapers to empower your research. However, that is just not enough. Therefore we added a completely new category: “products”!
There is a whole universe of research which you cannot access through reading scientific publications. And that is most of industry research. However, this type of research is reflected by product development and patents. The new category “products” gives you access to exactly this kind of hidden information.
Lipidomics is no longer a thing of the lab. It is out in the world. Now, you can learn about it!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.